|Bid||26.76 x 1400|
|Ask||26.86 x 800|
|Day's Range||25.83 - 27.18|
|52 Week Range||21.67 - 35.55|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.25|
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Allogene Therapeutics, Inc. (NASDAQ:ALLO) with a market-capitalization of US$3.2b, rarely draw their attention. However, generally ignored mid-capsRead More...
Phase 1 ALLO-501 Clinical Trial On-Track for Initiation in 1H 2019Trial Includes Dose Escalation to Determine the Optimal Dose of ALLO-501 and Use of ALLO-647 for.
NEW YORK, NY / ACCESSWIRE / March 8, 2019 / Allogene Therapeutics, Inc. (NASDAQ: ALLO ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 8, 2019 at 8:30 ...
In a race to develop so-called allogeneic cell therapies — designed to treat dozens of patients with one manufacturing batch made from cells of healthy donors — the company landed a 118,000-square-foot lease in Newark.
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it has entered into a lease agreement to develop a 118,000 square foot cell therapy manufacturing facility in Newark, California. "Building state-of-the-art manufacturing capabilities is at the core of our strategy to deliver readily available cell therapy faster, more reliably and at greater scale,” said Alison Moore, Ph.D., Chief Technical Officer of Allogene.
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at four investor conferences in February and March 2019. Except where noted, a live audio webcast of each event will be available on the Investors section of Allogene’s website, www.allogene.com. Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
The company filed in late September for a $75 million initial public offering but has yet to release any more information, even as a key partnership hits major milestones.
Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, in collaboration with its development partner Servier, an independent international pharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has cleared Allogene’s Investigational New Drug (IND) application for ALLO-501 in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
Messemer's expertise in working with clients in banking and finance and grappling with rapid change will be useful in her board service.
The new leader discusses staffing and recruiting in the pricey Bay Area as well as his favorite rock bands and the benefits he gets from performing in his own improv troop, Butter Boost.
NEW YORK, NY / ACCESSWIRE / January 14, 2019 / U.S. equities posted strong weekly gains, however, stock closed lower for the day on Friday on concerns over an ongoing U.S. government shutdown and worries ...
The South San Francisco company, which has quickly grown to 105 employees and raised more than a half-billion dollars, plans to site a cell manufacturing facility in the Bay Area.
Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.
The Cambridge biotech shattered records on Thursday night when it announced it had raised more than $604 million in an IPO, the largest ever in the sector.
The analysis showed that 82 percent (14/17) of patients who received a lymphodepletion regimen consisting of fludarabine, cyclophosphamide and an anti-CD52 mAb (FCA) achieved a complete remission (CR) or complete remission with incomplete blood recovery (CRi). In the four patients who received fludarabine and cyclophosphamide (FC) only, there was minimal UCART19 expansion and no response.
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.
SOUTH SAN FRANCISCO, Calif.-- -- Data Provide Insights in Preparation for Investigational New Drug Submissions Planned in 2019 for ALLO-501 in Non-Hodgkin Lymphoma and ALLO-715 in Multiple Myeloma Allogene Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, today announced that it will present data supporting its allogeneic ...
Nearly half of the 22 U.S. IPOs in October priced below their range, according to Renaissance Capital, which manages exchange-traded funds made up of IPO stocks. Several more were postponed.
The emerging cell therapy company Orgenesis Inc (ORGS) continues to prove they've got the right stuff, growing their revenue 50% in fiscal Q3 over the previous quarter and 143% compared to the previous year. The company just signed another high-profile Cell Therapy company, Iovance Biotherapeutics (IOVA), as a client, joining Crispr Therapeutics (CRSP) and Adaptimmune (ADAP) among others. As they continue to sign clients, grow revenue, and add global manufacturing capacity, valuation metrics suggest this NASDAQ listing could be substantially undervalued.